Bioheart, Inc. Report issue

For profit Phase 1 Phase 3
Founded: Sunrise FL United States (1999)
Status: Left NME R&D (2021)

Organization Overview

First Clinical Trial
2003
NCT00054678
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Alternative names

Bioheart, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

autologous skeletal myoblast (3 trials)

Drugs in Phase 1 Trials (2)

allogeneic adipose derived mesenchymal stem cell (2 trials)

platelet-rich plasma (1 trial)

Drugs in Other Trials (1)

autologous adipose-derived mesenchymal stem cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Coronary Artery Disease (Phase 1)

Heart Failure (Phase 3)

Infarction (Phase 3)

Myocardial Infarction (Phase 3)

Osteoarthritis (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 4